收购将Bruker Advanced Supercon业务转变为超导设备，超导体和高级技术的全球领导者，用于替代能源研究和下一代能源基础设施。
马萨诸塞州比勒里卡 - （业务线） - Bruker Advanced Supercon，Inc。（Bruker）今天宣布，它已关闭收购研究工具的一部分，该部分位于德国Bergisch-Gladbach的Varian Medical Systems的Accel Instruments GmbH子公司。
Varian于2007年1月收购了Accel，包括其研究工具（RI）和Proton Therapy的业务。RI业务的所有资产。由布鲁克（Bruker）和瓦里安（Varian）于2009年2月签署的资产交易于2009年4月1日结束。交易的财务条款未披露。
The RI business acquired by Bruker is a world leader in the development and manufacturing of a wide variety of advanced superconducting and other subunits and systems for physics and energy research, plus other scientific applications. RI products include electron and ion LINACs, superconducting and normal conducting accelerator cavities, insertion devices, other accelerator components, neutron source subunits, specialized superconducting magnets, superconducting (HTS and LTS) devices, X-ray and particle beamlines, as well as vacuum and cryosystems.
Accel Instruments GmbH由Udo Klein博士和Michael Peiniger博士于1993年成立，是西门子AG的衍生产品。布鲁克（Bruker）保留了克莱因（Klein）博士和佩尼格（Peiniger）博士为新收购的RI业务中的董事和少数股东，该业务已分为两个新的布鲁克子公司：
- RI研究工具GmbH专注于RF空腔和系统，线性加速器以及用于物理和能源研究的特殊产品。它由其管理团队拥有45％的拥有，而Bruker拥有55％。
- Bruker Advanced Supercon GmbH is focusing on low and high temperature superconducting devices, circular accelerator vacuum systems, beamlines, and X-ray optics businesses, as well as specialty superconducting magnets for physics, energy research, medical devices, crystal growth applications, etc. It is 100% owned by Bruker.
Bruker Advanced Supercon，Inc。首席执行官Burkhard Prause博士解释说：“这项收购开辟了我们Bruker Advanced Supercon业务历史上的重要新篇章。它为我们定位了我们在几个令人兴奋的市场中的快速收入和利润增长的定位，包括可再生能源研究，未来更稳定和节能的电网，下一代材料研究和制造以及尖端医疗设备的组件bob综合游戏.Bruker plans to expand our new business in growth markets such as HTS superconducting fault current limiters for energy grid stabilization, crystal growth magnets for next-generation semiconductors, and superconducting devices and other core RI technologies for large-scale scientific and energy research facilities. We also expect to continue to supply OEM products to Varian in support of its proton therapy business for advanced cancer treatment."
Mr. Tom Rosa, Senior Vice President and Chief Financial Officer of Bruker Advanced Supercon, Inc., added: “On an annualized basis, our newly acquired superconducting devices and energy research systems business is expected to generate revenue of greater than $25 million in year one, with near break-even results, and with significant growth potential in future years. The Bruker Advanced Supercon business is the smallest division of Bruker Corporation today, but we have ambitious plans for profitable growth, supported by global trends in energy research, scientific infrastructure investments, and recent advances in materials and medical sciences.”
Mr. Joerg Laukien, Chairman of Bruker Advanced Supercon, Inc., concluded: “The acquisition announced today provides our Bruker Advanced Supercon business with significant additional catalysts for profitable growth in complementary markets, and transforms Bruker into a broad-based global leader in superconducting devices, superconductors and advanced technologies for alternative energy research and next-generation energy infrastructure.”
About Bruker Advanced Supercon:
Bruker Advanced Supercon子公司Bruker Corporation（NASDAQ：BRKR）包括在德国，英国和美国的运营，以及新收购的Accel RI业务。德国的Bruker EAS GmbH每年生产并销售超过20,000英里的Niobium-Titanium（NBTI）和Niobium-Tin（NB3SN）LTS电线。德国的Bruker HTS GmbH是基于其广泛的HTS技术平台的1G BSSCO和2G YBCO HTS材料和设备的领先制造商。bob综合游戏Bruker HTS解决方案增强了电力网格和大量能量需求应用的可靠性和效率。其专有的Superfast™超导故障电流限制器（SFCL）具有增强电网可靠性的潜力，其HTS当前铅可以大大减少大型工业和研究磁铁的电气损失。bob娱乐平台Bruker HTS制造的导体和组件正在用于建造新一代紧凑的高功率设备，例如HTS电动机，发电机，电缆和变压器，以及用于医疗和研究应用的高场磁铁。英国的Hydrstatic Extrusions Ltd.为航空业提供了轻巧的Cuponal™指挥。Bruker Advanced Supercon，Inc。于2008年在美国开设了业务发展和客户支持业务。有关更多信息：www.advancedsupercon.com或者www.energie2point0.com.
布鲁克前锋陈述：
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure to foreign currency fluctuations. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements other than as required by law